Outcomes with early response to first-line treatment in patients with newly diagnosed multiple myeloma by Nidhi Tandon, Surbhi Sidana, S. Vincent Rajkumar, Morie A. Gertz, Francis K. Buadi, Martha Q. Lacy, Prashant Kapoor, Wilson I. Gonsalves, Angela Dispenzieri, Taxiarchis V. Kourelis, Rahma Warsame, David Dingli, Amie L. Fonder, Suzanne R. Hayman, Miriam A. Hobbs, Yi Lisa Hwa, Robert A. Kyle, Nelson Leung, Ronald S. Go, John A. Lust, Stephen J. Russell, and Shaji K. Kumar BloodAdv Volume 3(5):744-750 March 12, 2019 © 2019 by The American Society of Hematology

Nidhi Tandon et al. Blood Adv 2019;3:744-750 © 2019 by The American Society of Hematology

OS and PFS in patients who achieved ≥VGPR and <VGPR. OS and PFS in patients who achieved ≥VGPR and <VGPR. (A) PFS based on response after 2 cycles. ≥VGPR, n = 240; median PFS, 28 months; 95% CI, 22-31. <VGPR, n = 600; median PFS, 30 months; 95% CI, 27-32; P = .6. (B) PFS based on response after 4 cycles. ≥VGPR, n = 350; median PFS, 31 months; 95% CI, 27-35. <VGPR, n = 490; median PFS, 29 months; 95% CI, 26-31; P = .1. (C) PFS based on best response with first-line treatment. >VGPR, n = 552; median PFS, 33 months; 95% CI, 31-36. <VGPR, n = 288; median PFS, 22 months, 95% CI, 18-25; P < .001. (D) OS based on response after 2 cycles. ≥VGPR, n = 240; median OS, 78 months; 95% CI, 67-102. <VGPR, n = 600; median OS, 96 months; 95% CI, 80-104; P = .1. (E) OS based on response after 4 cycles. ≥VGPR, n = 350; median OS, 89 months; 95% CI, 72-105. <VGPR, n = 490; median PFS, 91 months; 95% CI, 77-102; P = .9. (F) OS based on best response with first-line treatment. ≥VGPR, n = 552; median OS, 102 months; 95% CI, 87-108. <VGPR, n = 288; median PFS, 77 months; 95% CI, 61-88; P = .003. Nidhi Tandon et al. Blood Adv 2019;3:744-750 © 2019 by The American Society of Hematology